BioSpace News Archive

One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug Administration for its lead asset, inebilizumab.

Arizona is not exactly the first place one thinks of when it comes to the life sciences. But, like many states and municipalities, Arizona and Phoenix, Arizona, are working hard to grow the life science industry. According to AZBio, bioscience companies in Arizona employed 25,686 people in 2016 in 1,310 individual businesses.

Recipharm has announced that its 2018 International Environmental Award will be presented to Dr. Bryan Brooks, Distinguished Professor in Environmental Science and Biomedical Studies at Baylor University in Waco, Texas.

Hitachi Chemical Diagnostics, Inc., a global leader in multiplex allergy in vitro diagnostics, announced today that it received 510 clearance from the U.S Food and Drug Administration for its new high capacity allergy testing instrument, OPTIGEN® AP 3600TM.

Privately-held Swedish pharmaceutical company Lobsor Pharmaceuticals AB is eying the U.S. market for a potential treatment for neurodegenerative diseases such as Parkinson’s disease.

Study to Evaluate Safety and Efficacy of Drug Seeking to Treat Those with Mild Cognitive Impairment or Mild Dementia

The FY19 Defense Appropriation provides $7.5 million to the Department of Defense Autism Research Program to provide support for research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders.

PDC*line Pharma grants exclusive license in South Korea and exclusive option in other Asian countries to LG Chem Life Sciences Company, for the development and commercialization of PDC*lung cancer vaccine for lung cancer

Topas Therapeutics GmbH, a Hamburg, Germany-based private platform company leveraging the natural tolerance induction capabilities of the liver, announced that the Company will participate at several conferences this spring.

Continued innovation and increased investment will become the theme of Chinese pharmaceutical enterprises’ development in 2019 with the continuous advancement of generic drug consistency evaluation, acceleration of review and approval, and implementation of procurement with target quantity.